2. Disease Areas
  3. Digestive System Disease
  4. Gastric Disease Peptic Ulcer Disease
  5. Gastric Ulcer

Gastric Ulcer

A gastric ulcer, also known as a stomach ulcer or peptic ulcer, is an open sore that develops in the lining of the stomach due to erosion by gastric acid and pepsin, often resulting from Helicobacter pylori infection. It is characterized by a deep lesion extending into the submucosa, with common symptoms including burning or gnawing abdominal pain, early satiety, bloating, burping, nausea, vomiting, loss of appetite, and unintentional weight loss. While H. pylori is the most frequent cause, other factors such as alcohol, NSAIDs, radiation, and chemicals can also contribute. Gastric ulcers are treatable and represent a form of peptic ulcer disease, which affects the digestive tract lining.

References:

Gastric Ulcer (25):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1820
    Zinc sulphate 7733-02-0 99.85%
    Zinc sulphate is an orally active inhibitor of tyrosinase and glutathione reductase. Zinc sulphate enhances the activity of dopachrome tautomerase. Zinc sulphate delays anagen-related eumelanin production, induces hair hypopigmentation in mice, and accelerates wound healing. Zinc sulphate can be used in research related to benign gastric ulcers. Zinc sulphate can be used in research related to rheumatoid arthritis.
    Zinc sulphate
  • HY-N0340
    Scopolamine butylbromide 149-64-4 99.97%
    Scopolamine butylbromide (Hyoscine butylbromide) is an orally active anticholinergic agent and spasmolytic. Scopolamine butylbromide binds with high affinity to rat cardiac M2 (Ki 83 nmol/L), hM2 (Ki 233 nmol/L), rat intestinal M3 (Ki 290 nmol/L) and hM3 (Ki 643 nmol/L) muscarinic receptors. Scopolamine butylbromide exerts a dose-dependent antagonistic effect on Carbachol-induced gastrointestinal smooth muscle spasm. Scopolamine butylbromide can be used for the research of abdominal colic and pain associated with gastrointestinal spasm, functional abdominal pain, chronic gastropathy and gastric ulcer.
    Scopolamine butylbromide
  • HY-N3031
    Grosvenorine 156980-60-8 99.64%
    Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer.
    Grosvenorine
  • HY-G0007
    Omeprazole sulfone 88546-55-8 99.23%
    Omeprazole sulfone (Omeprazole sulphone) is one of the major circulating metabolites of Omeprazole (HY-B0113) in vivo, and belongs to class 4 non-mutagenic impurities. Omeprazole sulfone does not bind to the aryl hydrocarbon receptor (AhR), nor does it induce the expression of CYP1A1 or CYP1A2. However, Omeprazole sulfone promotes the migration of gastric epithelial cells under basal conditions and reverses the inhibitory effect of Indomethacin (HY-14397) on cell migration. Omeprazole sulfone does not promote cell proliferation, nor does it upregulate COX-2 expression or activate signaling pathways such as ERK, P38 MAPK and PI3K. Omeprazole sulfone maintains basal ulcer healing under non-acid-dependent conditions and can be used in studies related to gastric ulcer repair.
    Omeprazole sulfone
  • HY-B0327
    Irsogladine 57381-26-7 99.88%
    Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice. Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer[5][6].
    Irsogladine
  • HY-182625
    GS-1160-180 111878-47-8
    GS-1160-180 is a PAF receptor antagonist. GS-1160-180 competes with PAF for receptor binding, with no activity against collagen or adenosine diphosphate-induced platelet aggregation. GS-1160-180 can be used for research on asthma, anaphylactic shock, gastric ulceration, and transplant rejection.
    GS-1160-180
  • HY-182431
    Wy 45086 87476-50-4
    Wy 45086 is a histamine H2 receptor antagonist. Wy 45086 blocks the H2 receptor signaling pathway and inhibits gastric acid secretion in experimental animals. Wy 45086 can be used in ulcer-related research.
    Wy 45086
  • HY-167141
    AY 29315 114394-28-4
    AY 29315 is a selective and orally active histamine H2-receptor antagonist. AY 29315 can inhibit astric acid secretion and shows antiulcer activity. AY 29315 can be used for the research of gastric ulcer.
    AY 29315
  • HY-N12717
    Casuarinin 79786-01-9 98.24%
    Casuarinin is an orally active antiproliferative, anti-inflammatory, antifungal, virucidal and gastroprotective agent. Casuarinin upregulates the expression of p21/WAF1, Fas/APO‑1, mFasL, sFasL and HSP‑70, arrests cell cycle, induces apoptosis and inhibits cancer cell proliferation. Casuarinin inhibits TNF‑α-induced phosphorylation of MAPK and activation of NF‑κB, downregulates the expression of iNOS, NF‑κB, COX‑2 and ICAM‑1, and reduces the production of proinflammatory mediators. Casuarinin attenuates ethanol-induced activation of caspase‑3 and elevation of TNF‑α, inhibits the growth of Candida albicans, and inhibits HSV‑2. Casuarinin can be used in research related to mammary adenocarcinoma, inflammatory skin diseases, gastric ulcers, candidiasis and herpes simplex virus infections.
    Casuarinin
  • HY-126941
    Hecogenin acetate 915-35-5 98.57%
    Hecogenin acetate is an orally active steroid saponin aglycone with extensive biological activities. Hecogenin acetate inhibits the phosphorylation of NF-κB and p38 MAPK signaling pathways, antagonizes TRPA1/TRPM8 channels, inhibits the production of pro-inflammatory cytokines, and has anti-inflammatory and analgesic effects. Hecogenin acetate inhibits the production of ROS and the activation of NLRP3 inflammasome; downregulates the expression of MMP-2, and has neuroprotective and anti-tumor activities. Hecogenin acetate enhances gastric mucosal defense and promotes ulcer healing. Hecogenin acetate can be used in combination with certain antibiotics to regulate bacterial efflux pumps and restore antibiotic sensitivity.
    Hecogenin acetate
  • HY-165131
    Δ7-Avenasterol 7212-91-1
    Δ7-Avenasterol (Delta-7-avenasterol) is a phytosterol that binds to prostaglandin E2 receptor (prostaglandin E2 receptor) and cyclooxygenase-2 (COX-2). Δ7-Avenasterol is applicable to research related to gastric ulcer, anti-inflammation and antioxidation.
    Δ7-Avenasterol
  • HY-N12378
    β-Patchoulene 514-51-2
    β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma.
    β-Patchoulene
  • HY-108515
    (+)-Igmesine hydrochloride 99.0%
    (+)-Igmesine hydrochloride (JO1784) is an orally active and selective σ1 receptor ligand with an IC50 of 39 nM. (+)-Igmesine hydrochloride binds σ1 receptors to activate G-proteins and modulate Ca2+ uptake. (+)-Igmesine (hydrochloride) attenuates ischaemia-induced nitric oxide synthase activity and hyperactivity. (+)-Igmesine hydrochloride can be used for the research of duodenal ulcers, gastric ulcers, and cerebral ischaemia.
    (+)-Igmesine hydrochloride
  • HY-W013331
    Deoxyartemisinin 72826-63-2 99.9%
    Deoxyartemisinin (2-Deoxyartemisinin) is an orally active anti-inflammatory and analgesic agent. Deoxyartemisinin selectively reduces the level of the pro-inflammatory cytokine TNF-α. Deoxyartemisinin alleviates neuropathic pain, inflammatory pain, and croton oil-induced ear edema.\nDeoxyartemisinin exerts an analgesic effect against thermal stimulation. Deoxyartemisinin has anti-ulcer activity. Deoxyartemisinin can be used in research related to inflammatory diseases, pain, and gastric ulcers.
    Deoxyartemisinin
  • HY-182393
    IGN-2098 126869-04-3
    IGN-2098 is an orally active, competitive histamine H2 receptor antagonist with a pA2 value of 7.32. IGN-2098 inhibits basal and stimulated gastric acid secretion. IGN-2098 accelerates ulcer healing, suppresses ulcer edge elevation, and protects gastric and duodenal mucosa from damage. IGN-2098 can be used in research related to gastric ulcers.
    IGN-2098
  • HY-137962
    Clanobutin 30544-61-7
    Clanobutin is an orally active pharmaceutically acceptable N-acylanilinobutyric acid compound. Clanobutin increases gastrointestinal enzyme secretion. Clanobutin tonicizes the cardiovascular system, increases internal organ blood circulation, and boosts heart force. Clanobutin suppresses stomach ulcer formation and exhibits anti-hepatotoxic activity.
    Clanobutin
  • HY-N18218
    Speranskoside 219917-70-1
    Speranskoside is a dual COX-2/15-LOX inhibitor with a COX-2 IC50 of 2.62 μg/mL and a 15-LOX IC50 of 5.51 μg/mL. Speranskoside can be used for the research of gastric ulcers.
    Speranskoside
  • HY-180397
    Orf 17910 87107-94-6
    ORF 17910 is a potent, long-acting, orally active histamine H2 receptor antagonist. ORF 17910 exhibits significant and prolonged acid-suppressing activity in dogs and rats. However, the cardiac depressant effect of ORF 17910 cannot be completely overcome at high concentrations. ORF 17910 may be used to study diseases such as gastric ulcers.
    Orf 17910
  • HY-106074
    Mexiprostil 88980-20-5
    Mexiprostil (MDL 646) is an orally active gastric protectant, being a synthetic analogue of Prostaglandin E1 (HY-B0131). Mexiprostil exhibits significant inhibition of gastric acid secretion caused by Histamine (HY-B1204) and Bethanechol (HY-B0406) in rats, dogs, and cats. Mexiprostil can also inhibit the increase in gastric acid secretion caused by Pentagastrin (HY-A0261) in cats, while it does not have this effect in dogs and rats. Mexiprostil does not cause pregnancy termination. Mexiprostil can be used for research on gastric ulcers.
    Mexiprostil
  • HY-105535
    Etintidine hydrochloride 71807-56-2
    Etintidine (BL-5641) hydrochloride is a potent orally active histamine H2-receptor antagonist. Etintidine hydrochloride can be used for gastrointestinal ulcer diseases research.
    Etintidine hydrochloride